# Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

> **NCT03805022** · PHASE3 · RECRUITING · sponsor: **Institut Bergonié** · enrollment: 351 (estimated)

## Conditions studied

- Non-metastatic Soft-tissue Sarcoma
- Resectable

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide or dacarbazine
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide or dacarbazine
- **DRUG:** At the discretion of the investigator

## Key facts

- **NCT ID:** NCT03805022
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-02-14
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 351 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03805022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03805022, "Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03805022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*